• Agios Pharmaceuticals Inc AGIO.OQ reported a quarterly adjusted loss of $1.44​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.72. The mean expectation of nine analysts for the quarter was for a loss of $1.69 per share. Wall Street expected results to range from $-1.84 to $-1.54 per share.

• Revenue rose 51.1% to $10.73 million from a year ago; analysts expected $9.33 million.

• Agios Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.44​.

• The company reported a quarterly loss of $96.52 million.

• Agios Pharmaceuticals Inc shares had fallen by 0.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $56.50

This summary was machine generated from LSEG data February 13 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)